TP53 and pancreatic ductal adenocarcinoma: Because the first published papers, mainly based on immunohistochemical findings, did not demonstrate p53 alterations, it has traditionally been considered that, unlike pancreatic ductal adenocarcinomas, ACCs do not harbor TP53 mutations.